Eur Ann Allergy Clin Immunol:过敏性鼻炎在渗出性中耳炎儿童中的患病率分析

2019-11-15 AlexYang MedSci原创

过敏性鼻炎在渗出性中耳炎儿童中的患病率在不同的国家中范围为82%到93%。之前的研究已经鉴定和证明了许多渗出性中耳炎的风险因子。然而,与过敏性鼻炎的相关性仍旧存在争议。最近,有研究人员确定了渗出性中耳炎儿童中过敏性鼻炎的患病率情况,并鉴定了渗出性中耳炎的相关风险因子,与过敏性鼻炎相关的常见过敏原,还确定了渗出性中耳炎儿童的听力阈值。研究共包括了130名儿童。研究发现,渗出性中耳炎儿童中过敏性鼻炎的

过敏性鼻炎在渗出性中耳炎儿童中的患病率在不同的国家中范围为82%到93%。之前的研究已经鉴定和证明了许多渗出性中耳炎的风险因子。然而,与过敏性鼻炎的相关性仍旧存在争议。

最近,有研究人员确定了渗出性中耳炎儿童中过敏性鼻炎的患病率情况,并鉴定了渗出性中耳炎的相关风险因子,与过敏性鼻炎相关的常见过敏原,还确定了渗出性中耳炎儿童的听力阈值。研究共包括了130名儿童。研究发现,渗出性中耳炎儿童中过敏性鼻炎的患病率在他们的研究群体中为80.3%,在这些儿童中,尘螨是最常见的过敏原(87.7%)。另外一个可能的风险因子是家庭成员人数超过4人(96%)。渗出性中耳炎最高能引起33dB的听力损失。然而,在开始过敏原治疗后第二次跟访中听力阈值具有统计学显著改善。另外,过敏性鼻炎组儿童中的听力阈值与非过敏性鼻炎组相比受显著的影响。

最后,研究人员指出,在渗出性中耳炎儿童中,过敏性鼻炎和更大的家庭是的共同风险因子。在渗出性中耳炎和过敏性鼻炎儿童中,听力损失明显。另外,听力阈值在进行医疗后显著改善。他们的研究澄清了过敏性鼻炎与渗出性中耳炎相关性的矛盾情况。

原始出处:

Saifudina N, Husaina S, Goha BS et al. Prevalence of allergic rhinitis in children with otitis media with effusion. Eur Ann Allergy Clin Immunol. 31 Oct 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047186, encodeId=0b48204e1865b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Oct 27 19:06:00 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250648, encodeId=8b301250648cf, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329309, encodeId=b3e31329309f9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344508, encodeId=81b11344508af, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375199, encodeId=32383e5199c3, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 16:52:37 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047186, encodeId=0b48204e1865b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Oct 27 19:06:00 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250648, encodeId=8b301250648cf, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329309, encodeId=b3e31329309f9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344508, encodeId=81b11344508af, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375199, encodeId=32383e5199c3, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 16:52:37 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047186, encodeId=0b48204e1865b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Oct 27 19:06:00 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250648, encodeId=8b301250648cf, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329309, encodeId=b3e31329309f9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344508, encodeId=81b11344508af, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375199, encodeId=32383e5199c3, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 16:52:37 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2019-11-17 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047186, encodeId=0b48204e1865b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Oct 27 19:06:00 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250648, encodeId=8b301250648cf, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329309, encodeId=b3e31329309f9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344508, encodeId=81b11344508af, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375199, encodeId=32383e5199c3, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 16:52:37 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047186, encodeId=0b48204e1865b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Oct 27 19:06:00 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250648, encodeId=8b301250648cf, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329309, encodeId=b3e31329309f9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344508, encodeId=81b11344508af, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Sun Nov 17 05:06:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375199, encodeId=32383e5199c3, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 16:52:37 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2019-11-15 14794e5bm67(暂无昵称)

    精彩

    0

相关资讯

Clin Respir J:哮喘和过敏性鼻炎儿童中与呼出一氧化氮相关的因素研究

导致呼出一氧化氮(FeNO)水平变化的相关因素在不同年龄段的哮喘儿童中仍具缺乏报道。最近,有研究人员在具有过敏性鼻炎的哮喘儿童中评估了与FeNO相关的因素和FeNO对吸入性类固醇的响应情况。研究包括了5岁到12岁的哮喘儿童。研究人员测试了FeNO、肺功能和对乙酰甲胆硷的支气管高反应性(BHR)、气源性过敏原的皮刺测试、血清中总免疫球蛋白E(T-lgE)和血液中的嗜酸性粒细胞水平,并评估了FeNO与

World Allergy Organ J:过敏性鼻炎历史和哮喘风险研究

在一些研究中,过敏性鼻炎被质疑是哮喘的一个风险因子,但是该相关性并没有很好的证实。最近,有研究人员通过一个系统的回顾和元分析提出了过敏性鼻炎与哮喘风险相关性的证据。研究人员在Medline、Scopus、ISI会议记录数据库和其他数据库中进行了搜索,截止时间为2019年2月,之后进行人工检索来鉴定报道相对风险评估和过敏性鼻炎和哮喘相关性置信区间的案例对照和群体研究,研究人员排除了代表性的额研究。研

World Allergy Organ J:老年人慢性鼻炎治疗中糠酸莫米松并不比生理盐水效果更好

与老龄化相关疾病的患病率正在增加,其中就有鼻部的问题。慢性鼻炎是老年人中最为常见的鼻部疾病之一。同时,过敏症状会因免疫退化而减少。最近,有研究人员评估了一种皮质类固醇鼻喷雾剂(糠酸莫米松)对鼻腔开放和鼻炎严重度以及生活质量的影响,并与生理盐水喷雾效果进行了比较。研究是一个开放标签随机研究,包括了不小于60岁的慢性鼻炎(过敏性和非过敏性鼻炎)患者。主要的终点是鼻腔开放的改善,次级结果包括了症状的严重

Mol Med Rep:Der p2‑A20 DNA疫苗能够减弱过敏性炎症

过敏性鼻炎(AR)是一种常见的疾病,需要更加方便,安全和有效的抗原特异性免疫疗法。最近,有研究人员调查了鼻内注射能够共表达der p2和a20蛋白的真核表达载体对过敏性鼻炎小鼠的治疗效果。研究人员通过纳米粒子包装pVAX1-Der p2-A20疫苗,并通过建立了Balb/c过敏性鼻炎小鼠模型。之后评估了DNA疫苗对鼻过敏炎症的治疗效果,并通过ELISA确定了lgE,slgE和lgG以及细胞因子水平

Int Forum Allergy Rhinol:类胆碱能神经元D-U87细胞能估促进过敏性鼻炎T辅助细胞2的极化

副交感神经过敏对过敏性鼻炎(AR)的严重度是有贡献的,但是潜在的神经免疫调控的精细机制仍旧不清楚。最近,有研究人员调查了胆碱能神经抑制剂对AR CD4+ T辅助细胞2(Th2)的极化的影响以及潜在的调控机制。研究人员建立了体外D-U87细胞和CD4+ T细胞的共培养模型。研究发现,Th2细胞比例在来源于AR患者的CD4+ T细胞与D-U87细胞共培养后显著增加,但是在异丙托溴铵(IB)处理后减少。

Sci Rep:过敏性鼻炎是胃食管反流病的一种风险因素

胃食管反流病(GERD)能够引起一些上呼吸道症状,并改变鼻咽粘膜的生理,而反过来上呼吸道疾病同样可能加剧GERD症状。长久以来,哮喘被认为是GERD的一种风险因素。根据相似的流行病学与病理生理学,哮喘和过敏性鼻炎(AR)通常被鉴定为联合气道疾病;然而,AR与GERD的相关性仍旧还没有阐明。最近,有研究人员评估了是否AR能够增加GERD的风险。研究人员从健康保险数据库中鉴定了诊断为AR的患者,时间为